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Background:  Nonvalvular atrial fibrillation (AF) is the most common cardiac dysrhythmia. It is well known that left atrial appendage thrombus 
(LAAT) is the most frequent source of embolic stroke (ES) in AF patients. Currently, the CHADS2 score is widely utilized to predict stroke risk. We 
tested the hypothesis that elevated Left Ventricular Filling Pressure (LVFP) mediates LAAT formation in AF. We evaluated whether BNP, a surrogate for 
LVFP, is a better predictor of LAAT than the CHADS2 score.
Methods:  We conducted a retrospective cohort study of 275 consecutive nonvalvular AF patients who underwent transesophageal 
echocardiography (TEE) to exclude LAAT. Pre-TEE data was collected, including CHADS2 score, BNP level and use of aspirin or warfarin. A 2-sided 
T-test was used to compare mean BNP levels in LAAT(+) vs. LAAT(-) patients.
Results:  Among 275 subjects, 23 (8.3%) had LAAT by TEE. Baseline characteristics in LAAT(+) and LAAT(-) subjects were similar for CHADS2 score 
(2.53 vs. 1.84, p=0.09) and antiplatelet use (66.7% vs. 49.5%, P=0.2). Warfarin was more commonly used in LAAT(+) patients (86.7% vs. 56.1%, 
p=0.02). Mean BNP levels were significantly higher in LAAT(+) than LAAT(-) subjects (2083 vs. 832, P =0.005). Multivariate logistic regression 
analysis demonstrated that BNP is predictive of LAAT independent of the CHADS2 score (p= 0.04 and 0.009), as well as the use of antiplatelet or 
warfarin. The ROC curve showed that BNP has a higher discriminatory capacity in predicting LAAT than the CHADS2 score (AUC 0.88 vs. 0.63) and 
that none of the patients with BNP ≤ 450 pg/dl had LAAT, regardless of the CHADS2 score [LR (-) = 0].
Discussion: These preliminary data suggest that BNP is both independent of- and superior to the CHADS2 score in predicting the formation of 
LAAT. Our study is limited by a low LAAT event rate, retrospective design. If proven by a prospective controlled outcome study, BNP has the potential 
to replace or complement the CHADS2 score in predicting stroke risk and determining the need for anticoagulation therapy. It may be possible to 
identify a cutoff value for BNP (≤ 450 pg/dl) below which LAAT formation and ES are highly unlikely, eliminating the need for anticoagulation in many 
patients.
